Monetizing Technology Leadership Nine-month results Scientific Excellence Operational Excellence Evotec SE, 9M 2025 results call, 05 November 2025 Agenda PAGE 3 1. 9M/Q3 review 2. Monetizing Technology Leadership 3. On track to reach 2028 outlook 4. Questions & Answers Disclaimer This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the "Company", "we," ...

H1 2025 Performance & Strategic Review - Evotec achieved > €40 million in annualized gross savings through Priority Reset initiatives[13] - Discovery & Preclinical Development (D&PD) experienced an 11% revenue decline due to soft demand for transactional business[19] - Just - Evotec Biologics (JEB) saw a 16% year-over-year revenue growth, driven by strong non-Sandoz/non-DOD business[19] - The company is implementing a new operating model[18] and focusing investments in technology leadership[13] Technology & Asset Monetization - Evotec is expanding its E.MPD (Electronic Medical Product Documentation) database, now encompassing ~27,000 patients across various therapeutic areas[40] - A non-binding term sheet was signed for the sale of Just - Evotec Biologics EU site in Toulouse to Sandoz, including purchase price consideration, technology license fees, development revenues, milestones, and royalties[19] - The company is pursuing an IP licensing model for its proprietary continuous manufacturing platform and J CHO cell line[50] Financials & Outlook - The company is ahead of its cost-out plan[13], with FY 2025 total cost-out target of €60+ million[29] - Total liabilities and lease obligations decreased to €462 million from €478 million (end of Q1 '25)[35] - The company expects revenue between €800 million[62] for FY2025 - The company aspires to achieve revenue CAGR of 8-12% and an adjusted EBITDA margin >20% by 2028[70]